BEFORE THE MEDICAL BOARD OF CALIFORNIA DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

In the Matter of the Accusation Against:)))
Bernard Songco Bacay, M.D.) Case No. 800-2014-008164
Physician's and Surgeon's Certificate No. A 76551)))
Respondent)))

DECISION

The attached Stipulated Settlement and Disciplinary Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on October 27, 2017.

IT IS SO ORDERED: September 29, 2017.

MEDICAL BOARD OF CALIFORNIA

Iamie Wright, J.D., Chair

Panel A

		,	
1	Xavier Becerra		
2	Attorney General of California MATTHEW M. DAVIS	•	
3	Supervising Deputy Attorney General JOHN S. GATSCHET		
4	Deputy Attorney General State Bar No. 244388		
5	California Department of Justice 1300 I Street, Suite 125		
6	P.O. Box 944255 Sacramento, CA 94244-2550		
7	Telephone: (916) 445-5230 Facsimile: (916) 327-2247		
8	Attorneys for Complainant		
9			
10	BEFORE THE MEDICAL BOARD OF CALIFORNIA DEPARTMENT OF CONSUMER AFFAIRS		
11			
12	STATE OF CALL	FURNIA	
13	In the Matter of the Accusation Against:	Case No. 800-2014-008164	
14	BERNARD BACAY, M.D.	OAH No. 2017041118	
15	22777 Craig Rd. Escalon, CA 95320	STIPULATED SETTLEMENT AND	
16	Physician's and Surgeon's Certificate No. A 76551,	DISCIPLINARY ORDER	
17	Respondent.		
18		!	
19			
20	IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-		
21	entitled proceedings that the following matters are true:		
22	<u>PARTIES</u>		
23	1. Kimberly Kirchmeyer ("Complainant") is the Executive Director of the Medical		
24	Board of California ("Board"). She brought this action solely in her official capacity and is		
25	represented in this matter by Xavier Becerra, Attorney General of the State of California, by John		
26	S. Gatschet, Deputy Attorney General.		
27	2. Respondent Bernard Bacay, M.D. ("Respondent") is represented in this proceeding		
28	by attorney Peter J. Kelly, whose address is:		

III

Peter J. Kelly Riggio, Mordaunt & Kelly 2509 West March Lane, Ste. 200 Stockton, CA 95207

3. On or about September 19, 2001, the Board issued Physician's and Surgeon's Certificate No. A 76551 to Respondent. The Physician's and Surgeon's Certificate was in full force and effect at all times relevant to the charges brought in Accusation No. 800-2014-008164, and will expire on August 31, 2017, unless renewed.

JURISDICTION

- 4. Accusation No. 800-2014-008164 was filed before the Board, and is currently pending against Respondent. The Accusation and all other statutorily required documents were properly served on Respondent on March 13, 2017. Respondent timely filed his Notice of Defense contesting the Accusation.
- 5. A copy of Accusation No. 800-2014-008164 is attached as exhibit A and incorporated herein by reference.

ADVISEMENT AND WAIVERS

- 6. Respondent has carefully read, fully discussed with counsel, and understands the charges and allegations in Accusation No. 800-2014-008164. Respondent has also carefully read, fully discussed with counsel, and understands the effects of this Stipulated Settlement and Disciplinary Order.
- 7. Respondent is fully aware of his legal rights in this matter, including the right to a hearing on the charges and allegations in the Accusation; the right to confront and cross-examine the witnesses against him; the right to present evidence and to testify on his own behalf; the right to the issuance of subpoenas to compel the attendance of witnesses and the production of documents; the right to reconsideration and court review of an adverse decision; and all other rights accorded by the California Administrative Procedure Act and other applicable laws.
- 8. Respondent voluntarily, knowingly, and intelligently waives and gives up each and every right set forth above.

CULPABILITY

- 9. Respondent admits the truth of each and every charge and allegation in Accusation No. 800-2014-008164.
- 10. Respondent agrees that his Physician's and Surgeon's Certificate is subject to discipline and he agrees to be bound by the Board's probationary terms as set forth in the Disciplinary Order below.

CONTINGENCY

- 11. This stipulation shall be subject to approval by the Medical Board of California. Respondent understands and agrees that counsel for Complainant and the staff of the Medical Board of California may communicate directly with the Board regarding this stipulation and settlement, without notice to or participation by Respondent or his counsel. By signing the stipulation, Respondent understands and agrees that he may not withdraw his agreement or seek to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not be disqualified from further action by having considered this matter.
- 12. The parties understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile signatures thereto, shall have the same force and effect as the originals.
- 13. In consideration of the foregoing admissions and stipulations, the parties agree that the Board may, without further notice or formal proceeding, issue and enter the following Disciplinary Order:

DISCIPLINARY ORDER

IT IS HEREBY ORDERED that Physician's and Surgeon's Certificate No. A 76551 issued to Respondent Bernard Bacay, M.D. is revoked. However, the revocation is stayed and Respondent is placed on probation for three (3) years on the following terms and conditions.

1. <u>CONTROLLED SUBSTANCES - MAINTAIN RECORDS AND ACCESS TO RECORDS AND INVENTORIES</u>. Respondent shall maintain a record of all controlled substances ordered, prescribed, dispensed, administered, or possessed by Respondent, and any recommendation or approval which enables a patient or patient's primary caregiver to possess or cultivate marijuana for the personal medical purposes of the patient within the meaning of Health and Safety Code section 11362.5, during probation, showing all of the following: 1) the name and address of the patient; 2) the date; 3) the character and quantity of controlled substances involved; and 4) the indications and diagnosis for which the controlled substances were furnished.

Respondent shall keep these records in a separate file or ledger, in chronological order. All records and any inventories of controlled substances shall be available for immediate inspection and copying on the premises by the Board or its designee at all times during business hours and shall be retained for the entire term of probation.

- 2. <u>EDUCATION COURSE</u>. Within 60 calendar days of the effective date of this Decision, and on an annual basis thereafter, Respondent shall submit to the Board or its designee for its prior approval educational program(s) or course(s) which shall not be less than 20 additional hours per year, for each year of probation. The educational program(s) or course(s) shall be aimed at correcting any areas of deficient practice or knowledge and shall be Category I certified. The educational program(s) or course(s) shall be at Respondent's expense and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of licensure. Following the completion of each course, the Board or its designee may administer an examination to test Respondent's knowledge of the course. Respondent shall provide proof of attendance for a total of 45 hours of CME of which 20 hours were in satisfaction of this condition.
- 3. PRESCRIBING PRACTICES COURSE. Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a course in prescribing practices approved in advance by the Board or its designee. Respondent shall provide the approved course provider with any information and documents that the approved course provider may deem pertinent. Respondent shall participate in and successfully complete the classroom component of the course not later than six (6) months after Respondent's initial enrollment. Respondent shall successfully

28 ///

complete any other component of the course within one (1) year of enrollment. The prescribing practices course shall be at Respondent's expense and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of licensure. The prescribing practices course shall be in addition to the requirements set forth requiring 20 additional hours of CME per year.

A prescribing practices course taken after the acts that gave rise to the charges in the Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board or its designee, be accepted towards the fulfillment of this condition if the course would have been approved by the Board or its designee had the course been taken after the effective date of this Decision.

Respondent shall submit a certification of successful completion to the Board or its designee not later than 15 calendar days after successfully completing the course, or not later than 15 calendar days after the effective date of the Decision, whichever is later.

4. MEDICAL RECORD KEEPING COURSE. Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a course in medical record keeping approved in advance by the Board or its designee. Respondent shall provide the approved course provider with any information and documents that the approved course provider may deem pertinent. Respondent shall participate in and successfully complete the classroom component of the course not later than six (6) months after Respondent's initial enrollment. Respondent shall successfully complete any other component of the course within one (1) year of enrollment. The medical record keeping course shall be at Respondent's expense and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of licensure. The medical record keeping course shall be in addition to the requirements set forth requiring 20 additional hours of CME per year.

A medical record keeping course taken after the acts that gave rise to the charges in the Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board or its designee, be accepted towards the fulfillment of this condition if the course would have

been approved by the Board or its designee had the course been taken after the effective date of this Decision.

Respondent shall submit a certification of successful completion to the Board or its designee not later than 15 calendar days after successfully completing the course, or not later than 15 calendar days after the effective date of the Decision, whichever is later.

5. MONITORING - PRACTICE/BILLING. Within 30 calendar days of the effective date of this Decision, Respondent shall submit to the Board or its designee for prior approval as a practice monitor(s), the name and qualifications of one or more licensed physicians and surgeons whose licenses are valid and in good standing, and who are preferably American Board of Medical Specialties (ABMS) certified. A monitor shall have no prior or current business or personal relationship with Respondent, or other relationship that could reasonably be expected to compromise the ability of the monitor to render fair and unbiased reports to the Board, including but not limited to any form of bartering, shall be in Respondent's field of practice, and must agree to serve as Respondent's monitor. Respondent shall pay all monitoring costs.

The Board or its designee shall provide the approved monitor with copies of the Decision(s) and Accusation(s), and a proposed monitoring plan. Within 15 calendar days of receipt of the Decision(s), Accusation(s), and proposed monitoring plan, the monitor shall submit a signed statement that the monitor has read the Decision(s) and Accusation(s), fully understands the role of a monitor, and agrees or disagrees with the proposed monitoring plan. If the monitor disagrees with the proposed monitoring plan with the signed statement for approval by the Board or its designee.

Within 60 calendar days of the effective date of this Decision, and continuing throughout each year of probation, Respondent's practice shall be monitored by the approved monitor. Respondent shall make all records available for immediate inspection and copying on the premises by the monitor at all times during business hours and shall retain the records for the entire term of probation.

If Respondent fails to obtain approval of a monitor within 60 calendar days of the effective

date of this Decision, Respondent shall receive a notification from the Board or its designee to cease the practice of medicine within three (3) calendar days after being so notified. Respondent shall cease the practice of medicine until a monitor is approved to provide monitoring responsibility.

The monitor(s) shall submit a quarterly written report to the Board or its designee which includes an evaluation of Respondent's performance, indicating whether Respondent's practices are within the standards of practice of medicine and whether Respondent is practicing medicine safely, billing appropriately or both. It shall be the sole responsibility of Respondent to ensure that the monitor submits the quarterly written reports to the Board or its designee within 10 calendar days after the end of the preceding quarter.

At the conclusion of each year of monitoring, the practice monitor shall submit a yearly written report to the Board which shall indicate whether the Respondent is practicing medicine safely and whether areas of practice deficiency have been corrected. If the practice monitor determines that Respondent no longer needs further practice monitoring and so states in the yearly written report and the Board in its sole discretion determines that further practice monitoring is no longer needed, this condition shall be deemed satisfied and will no longer be enforced as part of Respondent's probation. If the practice monitor identifies areas of continued deficiency that require additional monitoring and/or the Board determines additional practice monitoring is needed, this condition shall extend for an additional year of probation.

If the monitor resigns or is no longer available, Respondent shall, within 5 calendar days of such resignation or unavailability, submit to the Board or its designee, for prior approval, the name and qualifications of a replacement monitor who will be assuming that responsibility within 15 calendar days. If Respondent fails to obtain approval of a replacement monitor within 60 calendar days of the resignation or unavailability of the monitor, Respondent shall receive a notification from the Board or its designee to cease the practice of medicine within three (3) calendar days after being so notified. Respondent shall cease the practice of medicine until a replacement monitor is approved and assumes monitoring responsibility.

In lieu of a monitor, Respondent may participate in a professional enhancement program

///

approved in advance by the Board or its designee that includes, at minimum, quarterly chart review, semi-annual practice assessment, and semi-annual review of professional growth and education. Respondent shall participate in the professional enhancement program at Respondent's expense during the term of probation.

6. NOTIFICATION. Within seven (7) days of the effective date of this Decision, the Respondent shall provide a true copy of this Decision and Accusation to the Chief of Staff or the Chief Executive Officer at every hospital where privileges or membership are extended to Respondent, at any other facility where Respondent engages in the practice of medicine, including all physician and locum tenens registries or other similar agencies, and to the Chief Executive Officer at every insurance carrier which extends malpractice insurance coverage to Respondent. Respondent shall submit proof of compliance to the Board or its designee within 15 calendar days.

This condition shall apply to any change(s) in hospitals, other facilities or insurance carrier.

- 7. SUPERVISION OF PHYSICIAN ASSISTANTS AND ADVANCED PRACTICE

 NURSES. During the period of probation, Respondent shall be allowed to supervise two Nurse

 Practitioners that currently work in his practice, identified as Nurse Practitioner C. M. and Nurse

 Practitioner S. H.-T., but shall be prohibited from hiring and supervising additional physician assistant and advanced practice nurses.
- 8. <u>OBEY ALL LAWS</u>. Respondent shall obey all federal, state and local laws, all rules governing the practice of medicine in California and remain in full compliance with any court ordered criminal probation, payments, and other orders.
- 9. QUARTERLY DECLARATIONS. Respondent shall submit quarterly declarations under penalty of perjury on forms provided by the Board, stating whether there has been compliance with all the conditions of probation.

Respondent shall submit quarterly declarations not later than 10 calendar days after the end of the preceding quarter.

10. GENERAL PROBATION REQUIREMENTS.

Compliance with Probation Unit

Respondent shall comply with the Board's probation unit.

Address Changes

Respondent shall, at all times, keep the Board informed of Respondent's business and residence addresses, email address (if available), and telephone number. Changes of such addresses shall be immediately communicated in writing to the Board or its designee. Under no circumstances shall a post office box serve as an address of record, except as allowed by Business and Professions Code section 2021(b).

Place of Practice

Respondent shall not engage in the practice of medicine in Respondent's or patient's place of residence, unless the patient resides in a skilled nursing facility or other similar licensed facility.

License Renewal

Respondent shall maintain a current and renewed California physician's and surgeon's license.

Travel or Residence Outside California

Respondent shall immediately inform the Board or its designee, in writing, of travel to any areas outside the jurisdiction of California which lasts, or is contemplated to last, more than thirty (30) calendar days.

In the event Respondent should leave the State of California to reside or to practice.

Respondent shall notify the Board or its designee in writing 30 calendar days prior to the dates of departure and return.

- 11. <u>INTERVIEW WITH THE BOARD OR ITS DESIGNEE</u>. Respondent shall be available in person upon request for interviews either at Respondent's place of business or at the probation unit office, with or without prior notice throughout the term of probation.
- 12. <u>NON-PRACTICE WHILE ON PROBATION</u>. Respondent shall notify the Board or its designee in writing within 15 calendar days of any periods of non-practice lasting more than

30 calendar days and within 15 calendar days of Respondent's return to practice. Non-practice is defined as any period of time Respondent is not practicing medicine as defined in Business and Professions Code sections 2051 and 2052 for at least 40 hours in a calendar month in direct patient care, clinical activity or teaching, or other activity as approved by the Board. If Respondent resides in California and is considered to be in non-practice, Respondent shall comply with all terms and conditions of probation. All time spent in an intensive training program which has been approved by the Board or its designee shall not be considered non-practice and does not relieve Respondent from complying with all the terms and conditions of probation. Practicing medicine in another state of the United States or Federal jurisdiction while on probation with the medical licensing authority of that state or jurisdiction shall not be considered non-practice. A Board-ordered suspension of practice shall not be considered as a period of non-practice.

In the event Respondent's period of non-practice while on probation exceeds 18 calendar months, Respondent shall successfully complete the Federation of State Medical Board's Special Purpose Examination, or, at the Board's discretion, a clinical competence assessment program that meets the criteria of Condition 18 of the current version of the Board's "Manual of Model Disciplinary Orders and Disciplinary Guidelines" prior to resuming the practice of medicine.

Respondent's period of non-practice while on probation shall not exceed two (2) years.

Periods of non-practice will not apply to the reduction of the probationary term.

Periods of non-practice for a Respondent residing outside of California will relieve
Respondent of the responsibility to comply with the probationary terms and conditions with the
exception of this condition and the following terms and conditions of probation: Obey All Laws;
General Probation Requirements; Quarterly Declarations; Abstain from the Use of Alcohol and/or
Controlled Substances; and Biological Fluid Testing.

13. <u>COMPLETION OF PROBATION</u>. Respondent shall comply with all financial obligations (e.g., restitution, probation costs) not later than 120 calendar days prior to the completion of probation. Upon successful completion of probation, Respondent's certificate shall be fully restored.

- 14. <u>VIOLATION OF PROBATION</u>. Failure to fully comply with any term or condition of probation is a violation of probation. If Respondent violates probation in any respect, the Board, after giving Respondent notice and the opportunity to be heard, may revoke probation and carry out the disciplinary order that was stayed. If an Accusation, or Petition to Revoke Probation, or an Interim Suspension Order is filed against Respondent during probation, the Board shall have continuing jurisdiction until the matter is final, and the period of probation shall be extended until the matter is final.
- 15. <u>LICENSE SURRENDER</u>. Following the effective date of this Decision, if
 Respondent ceases practicing due to retirement or health reasons or is otherwise unable to satisfy
 the terms and conditions of probation, Respondent may request to surrender his or her license.
 The Board reserves the right to evaluate Respondent's request and to exercise its discretion in
 determining whether or not to grant the request, or to take any other action deemed appropriate
 and reasonable under the circumstances. Upon formal acceptance of the surrender, Respondent
 shall within 15 calendar days deliver Respondent's wallet and wall certificate to the Board or its
 designee and Respondent shall no longer practice medicine. Respondent will no longer be subject
 to the terms and conditions of probation. If Respondent re-applies for a medical license, the
 application shall be treated as a petition for reinstatement of a revoked certificate.
- 16. <u>PROBATION MONITORING COSTS</u>. Respondent shall pay the costs associated with probation monitoring each and every year of probation, as designated by the Board, which may be adjusted on an annual basis. Such costs shall be payable to the Medical Board of California and delivered to the Board or its designee no later than January 31 of each calendar year.

///

///

///

///

ACCEPTANCE

I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully discussed it with my attorney, Peter J. Kelly. I understand the stipulation and the effect it will have on my Physician's and Surgeon's Certificate. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Medical Board of California.

7 || 8 || DATED:

1

2

3

4

5

6

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

28

8/14/17

BERNARD BACAY, M.D.

I have read and fully discussed with Respondent Bernard Bacay, M.D. the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order. I approve its form and content.

DATED:

8/14/17

PETER J. KELLY
Attorney for Respondent

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Medical Board of California.

Dated:

3-15-17

Respectfully submitted,

XAVIER BECERRA Attorney General of California MATTHEW M. DAVIS

Supervising Deputy Attorney General

JOHN S. GATSCHET Deputy Attorney General Attorneys for Complainant

27 SA2017303226

33003874.doc

Exhibit A

Accusation No. 800-2014-008164

STATE OF CALIFORNIA MEDICAL BOARD OF CALIFORNIA SACRAMENTO March 12 20 17 BY D. Richard S STATE OF CALIFORNIA Case No. 800-2014-008164 ACCUSATION Respondent. **PARTIES**

XAVIER BECERRA · 1 Attorney General of California 2 MATTHEW M. DAVIS Supervising Deputy Attorney General 3 JOHN S. GATSCHET Deputy Attorney General 4 State Bar No. 244388 California Department of Justice 5 1300 I Street, Suite 125 P.O. Box 944255 6 Sacramento, CA 94244-2550 Telephone: (916) 445-5230 7 Facsimile: (916) 327-2247 8 Attorneys for Complainant 9

BEFORE THE MEDICAL BOARD OF CALIFORNIA DEPARTMENT OF CONSUMER AFFAIRS

12 13

10

11

In the Matter of the Accusation Against:

14 Bernard Bacay, M.D. 22777 CRAIG RD 15

ESCALON, CA 95320

Physician's and Surgeon's Certificate No. A 76551,

17

16

18

19

Complainant alleges:

20

21

22

23

24

25

26

27

- Kimberly Kirchmeyer ("Complainant") brings this Accusation solely in her official capacity as the Executive Director of the Medical Board of California, Department of Consumer Affairs ("Board").
- On or about September 19, 2001, the Medical Board issued Physician's and 2. Surgeon's Certificate No. A 76551 to Bernard Bacay, M.D. ("Respondent"). The Physician's and Surgeon's Certificate was in full force and effect at all times relevant to the charges brought herein and will expire on August 31, 2017, unless renewed.

28

111

JURISDICTION

- 3. This Accusation is brought before the Board, under the authority of the following laws. All section references are to the Business and Professions Code (Code) unless otherwise indicated.
- 4. Section 2227 of the Code provides that a licensee who is found guilty under the Medical Practice Act may have his or her license revoked, suspended for a period not to exceed one year, placed on probation and required to pay the costs of probation monitoring, or such other action taken in relation to discipline as the Board deems proper.
 - 5. Section 2234 of the Code, states, in pertinent part:

"The board shall take action against any licensee who is charged with unprofessional conduct. In addition to other provisions of this article, unprofessional conduct includes, but is not limited to, the following:

"(a) Violating or attempting to violate, directly or indirectly, assisting in or abetting the violation of, or conspiring to violate any provision of this chapter.

"

- "(c) Repeated negligent acts. To be repeated, there must be two or more negligent acts or omissions. An initial negligent act or omission followed by a separate and distinct departure from the applicable standard of care shall constitute repeated negligent acts.
- "(1) An initial negligent diagnosis followed by an act or omission medically appropriate for that negligent diagnosis of the patient shall constitute a single negligent act.
- "(2) When the standard of care requires a change in the diagnosis, act, or omission that constitutes the negligent act described in paragraph (1), including, but not limited to, a reevaluation of the diagnosis or a change in treatment, and the licensee's conduct departs from the applicable standard of care, each departure constitutes a separate and distinct breach of the standard of care.

"…"

///

///

6. Section 2266 of the Code states:

"The failure of a physician and surgeon to maintain adequate and accurate records relating to the provision of services to their patients constitutes unprofessional conduct."

DRUGS

- 7. <u>Hydrocodone with acetaminophen</u> Generic name for the drugs Vicodin, Norco, and Lortab. Hydrocodone with acetaminophen is classified as a short-acting opioid analgesic combination product used to treat moderate to moderately severe pain. Prior to October 6, 2014, Hydrocodone with acetaminophen was a Schedule III controlled substance pursuant to Code of Federal Regulations Title 21 section 1308.13(e). Hydrocodone with acetaminophen is a dangerous drug pursuant to California Business and Professions Code section 4022 and is a Schedule II controlled substance pursuant to California Health and Safety Code section 11055, subdivision (b).
- 8. Hydromorphone hydrochloride Generic name for the drug Dilaudid.

 Hydromorphone hydrochloride ("hel") is a potent opioid agonist that has a high potential for abuse and risk of producing respiratory depression. Hydromorphone hel is a short-acting medication used to treat severe pain. Hydromorphone hel is a Schedule II controlled substance pursuant to Code of Federal Regulations Title 21 section 1308.12. Hydromorphone hel is a dangerous drug pursuant to California Business and Professions Code section 4022 and is a Schedule II controlled substance pursuant to California Health and Safety Code section 11055(b).
- 9. <u>Fentanyl</u> Generic name for the drug Duragesic. Fentanyl is a potent, synthetic opioid analgesic with a rapid onset and short duration of action used for pain. The fentanyl transdermal patch is used for long term chronic pain. It has an extremely high danger of abuse and can lead to addiction as the medication is estimated to be 80 times more potent than morphine and hundreds of times more potent than heroin.² Fentanyl is a Schedule II controlled substance pursuant to Code of Federal Regulations Title 21 section 1308.12. Fentanyl is a dangerous drug

On October 6, 2014, Hydrocodone combination products were reclassified as Schedule II controlled substances. Federal Register Volume 79, Number 163. Code of Federal Regulations Title 21 section 1308.12.

http://www.cdc.gov/niosh/ershdb/EmergencyResponseCard 29750022.html

pursuant to California Business and Professions Code section 4022 and is a Schedule II controlled substance pursuant to California Health and Safety Code section 11055(c).

- 10. Oxymorphone hydrochloride Generic name for the drug Opana ER. Oxymorphone hydrochloride (hcl) is long-acting opioid analgesic used to relieve severe ongoing pain.

 Oxymorphone has a high risk for abuse and severe, possibly fatal, breathing problems if taken in the wrong dosage, strength, or with other drugs that might also affect breathing. Oxymorphone hydrochloride is a Schedule II controlled substance pursuant to Code of Federal Regulations Title 21 section 1308.12. Oxymorphone hydrochloride is a dangerous drug pursuant to California Business and Professions Code section 4022 and is a Schedule II controlled substance pursuant to California Health and Safety Code section 11055(b).
- 11. <u>Alprazolam</u> Generic name for the drug Xanax. Alprazolam is a short acting benzodiazepine used to treat anxiety. Alprazolam is a Schedule IV controlled substance pursuant to Code of Federal Regulations Title 21 section 1308.14. Alprazolam is a dangerous drug pursuant to California Business and Professions Code section 4022 and is a Schedule IV controlled substance pursuant to California Health and Safety Code section 11057(d).
- 12. <u>Diazepam</u> Generic name for Valium. Diazepam is a long-acting member of the benzodiazepine family used for the treatment of anxiety and panic attacks. Diazepam is a Schedule IV controlled substance pursuant to Code of Federal Regulations Title 21 section 1308.14(c) and Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022.
- 13. Zolpidem Tartrate Generic name for Ambien. Zolpidem Tartrate is a sedative and hypnotic used for short term treatment of insomnia. Zolpidem Tartrate is a Schedule IV controlled substance pursuant to Code of Federal Regulations Title 21 section 1308.14(c). It is a Schedule IV controlled substance pursuant to Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022.
- 14. <u>Tramadol</u> Generic name for the drug Ultram. Tramadol is an opioid pain medication used to treat moderate to moderately severe pain. Effective August 18, 2014, Tramadol was placed into Schedule IV of the Controlled Substances Act pursuant to Code of

Federal Regulations Title 21 section 1308.14(b). It is a dangerous drug pursuant to Business and Professions Code section 4022.

15. <u>Buprenorphine</u> – Generic name for the drug Butrans. Buprenorphine, a narcotic analgesic, when sold as Butrans, consists of an extended release transdermal film which is prescribed for the management of moderate to severe chronic pain in patients requiring a continuous, extended period, around-the-clock opioid analgesic. Buprenorphine is a Schedule III controlled substance pursuant to Code of Federal Regulations Title 21 section 1308.13, subdivision (e). Buprenorphine is a Schedule V controlled substance pursuant to Health and Safety Code section 11058, subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022.

FIRST CAUSE FOR DISCIPLINE

(Repeated Negligent Acts, Patients D.B. and V.E.3)

16. Respondent's license is subject to disciplinary action under section 2234, subdivision (c), of the Code, in that he committed repeated negligent acts during the treatment of two patients. The circumstances are as follows:

Patient D.B.

- 17. On or about March 15, 2011, Respondent initially saw Patient D.B. who presented for back pain and fatigue. Respondent noted that Patient D.B. was previously prescribed Norco and Tramadol. Respondent prescribed Amrix⁴. Respondent did not fully document Patient D.B.'s prior pain medication usage, prior response to pain medication and/or a prior substance abuse history. Respondent diagnosed Patient D.B. with back pain and fatigue.
- 18. On or about May 9, 2011, Respondent saw Patient D.B. for follow-up regarding back pain. Patient D.B. also mentioned issues with his left shoulder. Respondent prescribed a Butrans 5 mcg. per hour patch for pain control. The patient stated he preferred not to take Norco. Respondent did not fully document Patient D.B.'s prior pain medication usage, prior response to

Generically known as Cyclobenzaprine, a muscle relaxant.

³ Patients are identified by initial to protect their privacy. All witnesses will be fully identified in discovery.

pain medication and/or a prior substance abuse history before prescribing Butrans, a controlled substance. Respondent also prescribed Butrans on June 3, 2011, to Patient D.B.

- 19. On or about August 26, 2011, Respondent again saw Patient D.B. for back pain. Respondent prescribed Amrix and Tramadol. Respondent noted that Patient D.B. had not tried nonsteroidal anti-inflammatory drugs ("NSAIDS"), such as Naproxen or Ibuprofen, for pain. Respondent also noted that the patient prefers to not take Norco due to "addicting potential." Respondent did not fully document Patient D.B.'s prior pain medication usage, prior response to pain medication and/or a prior substance abuse history.
- 20. On or about February 27, 2012, Dr. M.B., Respondent's wife and business partner, authorized a prescription of 90 tablet of 10/325 mg. Norco for Patient D.B. On or about March 27, 2012, Dr. M.B. refilled the 90 tablets of 10/325 mg. Norco prescription. On or about March 26, 2012, Respondent documented seeing Patient D.B. for a lump in the right side of his throat. Respondent noted that Patient D.B.'s left shoulder had "tender stiffness" and that his left lower leg(s) were "tender." Respondent noted that Patient D.B. was now receiving 4 tablets of 10/325 mg. Norco per day and 1 tablet of 5 mg. Ambien per day. Respondent did not document why Patient D.B. was now being prescribed Norco despite Patient D.B. previously stating that he preferred to not be on the medication. Respondent did not fully document Patient D.B.'s prior pain medication usage, prior response to pain medication and/or a prior substance abuse history. Patient D.B. continued to receive refills of his Norco prescription following the appointment on February 27, 2012.
- 21. On or about September 24, 2012, Respondent saw Patient D.B. regarding a chronic history of recurrent shoulder pain. Respondent noted that Patient D.B. was taking 4 tablets of 10/325 mg. Norco and 4 tablets of 50 mg. Tramadol each day. Respondent noted that Patient D.B. was also receiving 1 tablet of 1 mg. of Xanax and 1 tablet of 12.5 mg. of Ambien from another medical practitioner, Dr. H. Respondent prescribed 30 tablets of 2 mg. of Valium as needed for muscle spasms. Respondent did not document why he was prescribing an additional benzodiazepine to Patient D.B. Respondent did not fully document Patient D.B.'s prior pain

22.

medication usage, prior response to pain medication and/or a prior substance abuse history when he prescribed a second benzodiazepine.

- 22. Beginning on or about December 20, 2012, Respondent began prescribing Opana E.R. and Dilaudid to Patient D.B. because of "worsening pain which now is constant." Respondent documented that he advised Patient D.B. to discontinue Norco. In capital letters it was noted that Patient D.B. had missed an appointment on December 6, 2012, due to his wife having a health emergency. Respondent did not fully document Patient D.B.'s prior pain medication usage, prior response to pain medication and/or prior substance abuse history when he changed Patient D.B.'s medications.
- 23. On or about December 20, 2012, Respondent prescribed 60 tablets of 10 mg. Opana ER and 45 tablets of 2 mg. Dilaudid to Patient D.B. On or about January 15, 2013, Respondent prescribed 45 tablets of 2 mg. Dilaudid to Patient D.B. On or about January 19, 2013, Respondent prescribed 60 tablets of 20 mg. Opana ER to Patient D.B. On or about February 4, 2013, Respondent refilled 90 tablets of 10/325 mg. Norco to Patient D.B. On or about February 13, 2013, Dr. M.B. prescribed 60 tablets of 20 mg. Opana ER and 45 tablets of 2 mg. Dilaudid to Patient D.B. On or about March 1, 2013, Respondent prescribed 60 tablets of 15 mg. Opana ER and 90 tablets of 10/325 mg. Norco to Patient D.B. On or about March 15, 2013, Respondent prescribed 60 tablets of 30 mg. Opana ER to Patient D.B. On or about March 18, 2013, Respondent prescribed 45 tablets of 2 mg. Dilaudid and 45 tablets of 10/325 mg. Norco to Patient D.B.
- 24. On or about April 13, 2013, Respondent prescribed 60 tablets of 30 mg Opana ER, 45 tablets of 10/325 mg. Norco, and 45 tablets of 2 mg. Dilaudid to Patient D.B. Assuming that the prescription provided by Respondent on April 13, 2013, was for one month, Patient D.B.'s morphine equivalent dose was approximately 207 MED⁵. Just six months earlier, on September 24, 2012, Patient D.B.'s morphine equivalent dose was approximately 70 MED. On or about May

⁵ An MED is a numerical standard against which most opioids can be compared, yielding a comparison of each medication's potency. An MED helps determine if the patient's opioid doses are excessive.

10, 2013, Respondent prescribed 60 tablets of 30 mg. Opana ER and 60 tablets of 10/325 mg. Norco to Patient D.B. Respondent failed to document why he had prescribed two short acting opioids, Norco and Dilaudid, at the same time to Patient D.B. between January 2013 and April 2013. Respondent failed to fully document Patient D.B.'s prior pain medication usage, prior response to pain medications and/or a prior substance abuse history when he increased Patient D.B.'s opioid prescriptions.

Patient V.E.

- 25. The Board has obtained all of Patient V.E.'s certified medical records between January 9, 2009, and October 5, 2015. There are approximately 41 clinical visits documented in Patient V.E.'s medical chart. Approximately 36 of the clinical visits were conducted by Respondent. On or about January 30, 2009, Respondent admitted Patient V.E. to the hospital for pneumonia. Respondent documented that Patient V.E. was currently being prescribed a 75 mcg./hr. Fentanyl patch for pain. The medication list at hospital discharge on February 2, 2009, notes that Patient V.E. was being discharged on a 100 mcg./hr. Fentanyl patch. On or about February 6, 2009, Respondent prescribed 10 patches 50 mcg./hr. Fentanyl patches to Patient V.E. Respondent continued to prescribe 10 patches of 50 mcg./hr. Fentanyl patches to Patient V.E. on a monthly basis through October 5, 2015.
- 26. Despite prescribing Fentanyl on a monthly basis to Patient V.E. between February 2009 and October 2015, a review of Patient V.E.'s medical chart reveals that Respondent failed to document Patient V.E.'s current pain assessment at each clinical visit. Patient V.E.'s medical records do not contain any documentation related to substance abuse history or any history of prior pain management treatments. There is no documentation in Patient V.E.'s medical records regarding Patient V.E.'s response to Fentanyl and there is no evidence that Respondent performed a periodic review of Patient V.E.'s course of pain treatment.
 - 27. Respondent's actions represented repeated negligent acts for the following reasons:
- 1. Failure to adequately document Patient D.B.'s substance abuse history, prior alcohol intake, and history of prior pain treatments in the medical records between March 15, 2011, and May 10, 2013, was a departure from the standard of care;

(BERNARD BACAY, M.D.) ACCUSATION NO. 800-2014-008164

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Medical Board of California issue a decision:

- 1. Revoking or suspending Physician's and Surgeon's Certificate Number A 76551, issued to respondent Bernard Bacay, M.D.;
- 2. Revoking, suspending or denying approval of respondent Bernard Bacay, M.D.'s authority to supervise physician assistants, pursuant to section 3527 of the Code, and advanced practice nurses;
- 3. Ordering respondent Bernard Bacay, M.D., if placed on probation, to pay the Board the costs of probation monitoring; and
 - 4. Taking such other and further action as deemed necessary and proper.

DATED: March 13, 2017

KIMBERLY KIRCHMEYER

Executive Director

Medical Board of California
Department of Consumer Affairs

State of California
Complainant

SA2017303226 32758907.doc